secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001372514-23-000159
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M
--------------------------------------------------------------------------------

- ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.
- Company plans Phase 2 trials for RP (ABACUS-2), Choroideremia, and Stargardt disease in 2024.
- Q3 2023 net loss $5.8M vs $5.1M in Q3 2022; loss increase driven by non-cash impairment of KIO-101/201.
- Cash and equivalents $5.4M, plus $1.3M tax receivables; runway into May 2024; $9.6M available on equity line.
- Raised $6.3M in funding and $1.2M in tax incentives during first half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/0001372514-23-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/kprx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer